BC Week In Review | Mar 30, 2018
Financial News

Addex raises $43M

Addex Therapeutics Ltd. (SIX:ADXN) raised CHF41 million ($43 million) on March 29 through the sale of 13 million shares at CHF3.13 to New Enterprise Associates, New Leaf Venture Partners, CAM Capital and clients of Semper...
BC Extra | Mar 29, 2018
Financial News

Addex raises $43M

Addex Therapeutics Ltd. (SIX:ADXN) raised CHF41 million ($43 million) Thursday through the sale of 13 million shares at CHF3.13 to New Enterprise Associates, New Leaf Venture Partners, CAM Capital and clients of Semper Finance Group...
BC Week In Review | Aug 24, 2015
Clinical News

Addex preclinical data

In mice, 50 mg/kg oral dipraglurant led to anxiolytic effects in the elevated plus maze (EPM) test and the stress-induced hyperthermia (SIH) test. Additionally, 30 and 50 mg/kg dipraglurant led to antidepressant effects in the...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Week In Review | Apr 29, 2013
Clinical News

Addex preclinical data

In a mouse model of primary generalized torsion dystonia 1, oral dipraglurant dose-dependently reduced abnormal neuronal activity induced by quinpirole, a dopamine D2 receptor agonist. Data will be presented at the Dystonia meeting in Rome...
BC Extra | Oct 13, 2012
Financial News

Addex raises CHF9.6 million

Addex Therapeutics Ltd. (SIX:ADXN) said late Friday that it raised CHF9.6 million ($10.3 million) through the sale of 918,025 shares at CHF10.50 per share in a private placement to institutional investors. Jefferies was placement agent....
BioCentury | Sep 10, 2012
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/7 cls Addex Therapeutics Ltd. (SIX:ADXN) Wedbush Christopher Marai New Outperform 21% CHF9.20 Marai set a CHF28 target. He believes the "primary value driver"...
BioCentury | Jul 2, 2012
Finance

2Q Stock Wrap-Up: Magic in mid-caps

Mid-caps performed best last quarter, with four companies gaining more than 50%. Other segments largely held on to their 1Q gains, except for companies valued below $200 million, which fell 15% in the quarter and...
BC Week In Review | Apr 16, 2012
Company News

Addex Therapeutics neurology news

Addex will restructure and reduce headcount by up to 28 (33%) from 85 to reduce costs. Addex said it will disclose further details on the restructuring after a consultation period required by Swiss law, which...
BC Extra | Apr 13, 2012
Company News

Addex restructuring

Addex Therapeutics (SIX:ADXN) said late Friday it plans to restructure and reduce headcount by up to 28 (33%) from about 85 to reduce costs. Addex said it will disclose further details on the restructuring after...
Items per page:
1 - 10 of 35